Hyperlipidemias: Clinical Trials

34 trials for Hyperlipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 terminated. 34 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 334Terminated 34

Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Pelacarsen - Hyperlipoproteinemia (a)
Phase 3TerminatedNovartis Pharmaceuticals412023-09-292026-11-10
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedAmgen2592019-05-092023-03-27
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
Evacetrapib, Ezetimibe, Atorvastatin - Hypercholesterolemia
Phase 3TerminatedEli Lilly and Company1492015-01-012018-10-09
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
Evacetrapib, Placebo - Hypercholesterolemia
Phase 3TerminatedEli Lilly and Company542014-11-012018-10-09
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
Evacetrapib, Atorvastatin, Ezetimibe - Hyperlipidemia
Phase 3TerminatedEli Lilly and Company3662014-10-012019-10-08
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
bococizumab (PF-04950615), Placebo - Cardiovascular Disease
Phase 3TerminatedPfizer105642013-10-292019-05-01
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
bococizumab (PF-04950615), Placebo - Cardiovascular Disease
Phase 3TerminatedPfizer167842013-10-292018-07-11
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
Anacetrapib, Placebo - Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia
Phase 3TerminatedMerck Sharp & Dohme LLC22013-06-012015-06-01
Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Placebo, Eprotirome - Heterozygous Familial Hypercholesterolaemia
Phase 3TerminatedKaro Bio AB2362011-10-012012-09-03
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM) - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC11392011-05-012019-02-06
Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill - Hypercholesterolemia
Phase 3TerminatedUniversity of California, Los Angeles132011-03-222019-02-12
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
Extended-release niacin/laropiprant (ERN/LRPT), Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC11732011-03-012024-05-22
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT) - Primary Hypercholesterolemia, Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC9772011-02-042018-08-16
Ezetimibe in Patients Hypo-responsive to Statins
Ezetimibe, Atorvastatin - High Cholesterol, Coronary Artery Disease
Phase 3TerminatedUniversity of California, San Diego22009-09-012019-08-21
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
AVE5530, Placebo - Hypercholesterolemia
Phase 3TerminatedSanofi6432008-10-012016-05-16
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
AVE5530, atorvastatin, placebo - Hypercholesterolemia
Phase 3TerminatedSanofi17362008-08-012016-05-16
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia
25 mg/day AVE5530, 50 mg/day AVE5530, placebo - Hypercholesterolemia
Phase 3TerminatedSanofi10152008-07-012016-05-16
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
AVE5530, Placebo - Hypercholesterolemia
Phase 3TerminatedSanofi8262008-07-012016-05-16
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia
Lapaquistat acetate, Placebo - Hypercholesterolemia
Phase 3TerminatedTakeda6572007-10-012012-05-24
INdians Followed for INtensive Lipid Lowering Treatment and Its safetY
ezetimibe, Comparator: Simvastatin 20, 40 and 80 mg, Comparator: Atorvastatin - Hypercholesterolemia
Phase 3TerminatedSunnybrook Health Sciences Centre642007-08-012011-07-28

Showing 20 of 34. Sign in to see all of them.

Narrower conditions

Hypercholesterolemia (22)  ·  Dyslipidemias (7)  ·  Cardiovascular Diseases (4)  ·  Hyperlipoproteinemia Type II (4)  ·  Coronary Artery Disease (2)  ·  Myocardial Infarction (2)  ·  Stroke (2)  ·  Atherosclerosis (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Homozygous Familial Hypercholesterolemia (1)  ·  Hyperlipoproteinemia Type III (1)  ·  Hyperlipoproteinemias (1)  ·  Hypertriglyceridemia (1)

Broader conditions

Lipid Metabolism Disorders (34)  ·  Metabolic Diseases (34)  ·  Nutritional and Metabolic Diseases (34)  ·  Dyslipidemias (27)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Genetic Diseases, Inborn (5)  ·  Hyperlipoproteinemias (5)  ·  Metabolism, Inborn Errors (5)  ·  Vascular Diseases (5)  ·  Heart Diseases (4)  ·  Lipid Metabolism, Inborn Errors (4)  ·  Myocardial Ischemia (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Arterial Occlusive Diseases (3)

Interventions

Atorvastatin (11)  ·  Simvastatin (6)  ·  Ezetimibe (5)  ·  1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (4)  ·  MK-0524 (4)  ·  torcetrapib (4)  ·  evacetrapib (3)  ·  Ezetimibe, Simvastatin Drug Combination (2)  ·  Niacin (2)  ·  Rosuvastatin Calcium (2)  ·  bococizumab (2)  ·  3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (1)  ·  Fenofibrate (1)  ·  Fluvastatin (1)  ·  Lovastatin (1)

Sponsors

Pfizer (6)  ·  Merck Sharp & Dohme LLC (5)  ·  Sanofi (4)  ·  Takeda (4)  ·  Eli Lilly and Company (3)  ·  Organon and Co (2)  ·  Amgen (1)  ·  Drug Commission of the German Medical Association (1)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)  ·  Karo Bio AB (1)  ·  Novartis Pharmaceuticals (1)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  University of California, Los Angeles (1)  ·  University of California, San Diego (1)

Countries

United States (18)  ·  Canada (9)  ·  France (6)  ·  Israel (6)  ·  Netherlands (6)  ·  Czechia (5)  ·  Puerto Rico (5)  ·  Russia (5)  ·  Australia (4)  ·  Belgium (4)  ·  Germany (4)  ·  Hungary (4)  ·  Poland (4)  ·  Slovakia (4)  ·  South Africa (4)

Top investigators

David Heber, MD, PhD (1)  ·  Davidson Michael, MD (1)  ·  Heiner K. Berthold, MD, PhD (1)  ·  John Kastelein, Professor (1)  ·  Ori Ben-Yehuda, MD (1)

Results publications

PMID 21518985, PMID 28304242, PMID 29685591, PMID 29716940, PMID 35277540, PMID 16705107, PMID 17407645, PMID 17630038, PMID 19029469, PMID 21613319, PMID 24731671, PMID 28412650, PMID 37565307

NIH funding

2005 (2), 2023 (1)